Informace o publikaci

Factors affecting mortality in COVID-19-associated pulmonary aspergillosis: An international ID-IRI study

Autoři	SAHIN Meyha YILMAZ Mesut MERT Ali EMECEN Ahmet Naci AL MASLAMANI Muna A Rahman S. HASHIM Samar Mahmoud A ITTAMAN Ajithkumar Valooparambil WADI Al Ramahi Jamal SZABO Balint Gergely KONOPNICKI Deborah ELIK Dilsah Baskol LAKATOS Botond SIPAHI Oguz Resat KHEDR Reham JALAL Sabah PSHENICHNAYA Natalia MAGDALENA Dumitru Irina EL-KHOLY Amani KHAN Ejaz Ahmed ALKAN Sevil HAKAMIFARD Atousa SINCAN Gulden ESMAOGLU Aliye MAKEK Mateja Jankovic GURBUZ Esra LISKOVA Anna ALBAYRAK Ayse STEBEL Roman ULUSOY Tulay Unver RIPON Rezaul Karim MOROTI Ruxandra DASCALU Cosmin RASHID Naveed CORTEGIANI Andrea BAHAD Zeynep ERDEM Hakan
Rok publikování	2024
Druh	Článek v odborném periodiku
Časopis / Zdroj	Heliyon
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://www.sciencedirect.com/science/article/pii/S2405844024103568?via%3Dihub
Doi	http://dx.doi.org/10.1016/j.heliyon.2024.e34325
Klíčová slova	COVID-19; COVID-19-associated aspergillosis; Intensive care unit; Mortality
Popis	Background: This study aimed to identify factors that influence the mortality rate of patients with coronavirus disease (COVID-19)-associated pulmonary aspergillosis (CAPA). Methods: In this cross-sectional study, data from 23 centers across 15 countries, spanning the period of March 2020 to December 2021, were retrospectively collected. The study population comprised patients who developed invasive pulmonary aspergillosis while being treated for COVID-19 in the intensive care unit. Cox regression and decision tree analyses were used to identify factors associated with mortality in patients with CAPA. Results: A total of 162 patients (males, 65.4 %; median age: 64 [25th-75th: 54.0-73.8] years) were included in the study, of whom 113 died during the 90-day follow-up period. The median duration from CAPA diagnosis to death was 12 (25th-75th: 7-19) days. In the multivariable Cox regression model, an age of >= 65 years (hazard ratio [HR]: 2.05, 95 % confidence interval [CI]: 1.37-3.07), requiring vasopressor therapy at the time of CAPA diagnosis (HR: 1.80, 95 % CI: 1.17-2.76), and receiving renal replacement therapy at the time of CAPA diagnosis (HR: 2.27, 95 % CI: 1.35-3.82) were identified as predictors of mortality. Decision tree analysis revealed that patients with CAPA aged >= 65 years who received corticosteroid treatment for COVID-19 displayed higher mortality rates (estimated rate: 1.6, observed in 46 % of patients). Conclusion: This study concluded that elderly patients with CAPA who receive corticosteroids are at a significantly higher risk of mortality, particularly if they experience multiorgan failure.